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Abstract 
Ewing sarcoma (EWS) is the second most frequent pediatric malignant bone tumor. EWS patients 
have not seen any major therapeutic progress in the last thirty years, in particular in the case of 
metastatic disease, which requires new therapeutic strategies. The pro-apoptotic cytokine TNF-
Related Apoptosis Inducing Ligand (TRAIL) can selectively kill tumor cells while sparing normal cells, 
making it a promising therapeutic tool in several types of cancer. However, certain EWS cell lines 
appear resistant to recombinant human (rh) TRAIL-induced apoptosis. We therefore hypothesized 
that a TRAIL presentation at the surface of the carrier cells might overcome this resistance and 
trigger apoptosis. For this purpose, human adipose mesenchymal stromal/stem cells (MSC) 
transfected in a stable manner to express full-length human TRAIL were co-cultured with several 
human EWS cell lines, inducing apoptosis by cell-to-cell contact even in cell lines initially resistant to 
rhTRAIL or AMG655, an antibody agonist to the death receptor, DR5. In vivo, TRAIL delivered by 
MSCs was able to counteract tumor progression in two orthotopic models of Ewing sarcoma, 
associated with caspase activation, indicating that a cell-based delivery of a potent apoptosis-
inducing factor could be relevant in EWS. 
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Introduction 
Ewing sarcoma (EWS), the second most common malignant bone tumor in pediatric patients after 
osteosarcoma, is a rare form of cancer. It is highly metastatic and causes serious disruption to bone 
remodeling. EWS is identified by a chromosomal translocation between the EWS gene on 
chromosome 22 and a member of the ETS transcription factor family, more often FLI1 on 
chromosome 11, leading to production of a fusion protein which behaves like an aberrant 
transcription factor1. The resulting fusion protein, EWS-FLI1, directly or indirectly modulates the 
expression of many genes, altering several cell functions such as cell cycle (by targeting p21/CDKN1A, 
Cyclin D and E, p57/KIP2, TGFα-, IGF- or MAPK signaling pathways) or apoptosis (by targeting capase3 
and members of the TNFα, IGF-1 and TGFβ signaling pathways)2. Transformed EWS cells appear as 
small, round and undifferentiated, and they are involved in major disruption of bone structure, with 
severe osteolytic lesions. 
The current therapeutic approach consists of surgery, neoadjuvant and adjuvant chemotherapy, and 
in some cases radiotherapy. The 5-year survival rate has barely changed in the past 30 years, and 
remains at around 70% for localized forms3. However, the rate falls drastically to around 20% for 
groups of metastatic patients or poor responders to chemotherapy. New avenues of research have 
been opened by using TNF-Related Apoptosis Inducing Ligand (TRAIL), a pro-apoptotic cytokine from 
the TNF superfamily. TRAIL can bind to five receptors: two death receptors - TRAIL-R1 (Death 
Receptor 4: DR4) and TRAIL-R2 (DR5) - two decoy receptors that do not transmit the death signal but 
that can confer resistance toward TRAIL-induced apoptosis - TRAIL-R3 (Decoy Receptor 1: DcR1) and 
TRAIL-R4 (DcR2) - and the soluble osteoprotegerin (OPG). TRAIL, by binding to DR4 and DR5, is able 
to induce apoptosis of tumor cells by activating the recruitment and cleavage of pro-caspase-8 in a 
complex called Death-Inducing Signaling Complex (DISC). A recruitment and activation cascade leads 
to tumor cell death by the extrinsic apoptosis pathway. This mechanism can be amplified in certain 
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cell types by activating the intrinsic apoptosis pathway, depending on the mitochondria and 
apoptosome. Both pathways lead to the final cleavage of pro-caspase-3 into active caspase-34. 
In the early 2000s, it was reported that several cell lines derived from EWS are sensitive to TRAIL-
induced apoptosis in vitro5–7. Based on these studies, xenograft models showed that recombinant 
human (rh) TRAIL or death receptor (DR)5 agonists can significantly reduce tumor volume, preventing 
osteolytic lesions and increasing animal survival8,9. Early clinical trials revealed that rhTRAIL had 
promising effects, but its sub-optimal bioavailability due to rapid clearance prevented the 
introduction of rhTRAIL into clinical use10,11. Of the various strategies for increasing the therapeutic 
effect of TRAIL, using cells carrying TRAIL looks promising12–17. These transporter cells can be adipose-
derived mesenchymal stromal/stem cells (AD-MSC), modiﬁed to encode human TRAIL18,19. Here, we 
further challenge the promising therapeutic potential of AD-MSC as TRAIL cellular vectors in a variety 
of EWS cell lines in vitro, additionally assessing this anti-cancer gene delivery approach in two 
different orthotopic in vivo models of EWS. 
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Materials and Methods 
Cell cultures 
Tumor Cell Lines. Six human EWS cell lines: A-673, SK-N-MC, SK-ES-1, and RD-ES cell lines (kindly 
provided by Dr S. Burchill, Children's Hospital, Leeds, UK) and EW-24 and TC-71 cell lines (provided by 
Dr O. Delattre, INSERM U830, Paris, France) were used. The A-673, SK-ES-1, and RD-ES cell lines were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Lonza, Basel, Switzerland) with 5% fetal 
bovine serum (FBS; Thermo Scientific, Waltham, USA) and 2 mmol/L L-glutamine (Lonza). EW-24, SK-
N-MC and TC-71 cells were cultured in Rosewell Park Millenium Institute (RPMI, Lonza) medium with 
5% FBS and 2 mmol/L L-glutamine.  
Mesenchymal Stromal/Stem Cells. Adipose-Derived (AD)-MSC expressing green fluorescent protein 
(GFP) only or TRAIL with GFP (named respectively MSC-GFP and MSC-TRAIL) were obtained as 
previously described18,20. In this setting, AD-MSC were cultured in αMEM (Lonza) supplemented with 
10% FBS (Thermo Scientific), 2 mmol/L L-glutamine and 2ng/mL basic Fibroblast Growth Factor 
(bFGF; R&D Systems, Minneapolis, USA). 
 
In Vitro Experiments 
Human TRAIL ELISA Assay. Ninety-six-well plates were coated with polyclonal anti-human TRAIL 
antibody (0.2 μg/well, R&D Systems) overnight at room temperature, washed and then incubated for 
1 h with a blocking solution (1% bovine serum albumin/Phosphate buffered saline (PBS)). After 
washing, the wells were incubated at room temperature with supernatant or protein lysate from 
MSC-GFP and MSC-TRAIL for 2 h, followed by a 2-h incubation with Biotin-SP–conjugated Donkey 
Anti-Human TRAIL IgG (1:180; R&D Systems). Detection was carried out by incubating the wells with 
streptavidin–horseradish peroxidase (1:200; R&D systems) for 30 min. The reaction was stopped by 
adding 50 μL of 1 mol/L H2SO4. Absorbance was then measured at 410nm using a VICTOR2 Multilabel 
counter (Perkin-Elmer). The ELISA detection limit was 0.02 ng/mL.  
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Quantitative RT-PCR. Total RNA was extracted from cultured cells (after 48h of treatment) using a 
Direct-zol™ RNA MiniPrep Kit (Zymo Research). Two μg of total RNA was reverse transcribed using 
the Maxima H Minus First Strand cDNA Synthesis Kit (Life Technology). Real-time monitoring of 
complementary DNA (cDNA) PCR amplification was performed using DNA primers on CFX96 (Bio-Rad 
Laboratories) with SYBRGreen detection according to the manufacturer’s recommendations. PCR 
amplifications involved 39 cycles of 30 s at 98°C, 15s at 95°C and 30s at 60°C. Expression of the target 
genes was normalized to that of the endogenous control glyceraldehyde 3-phosphate 
dehydrogenase. The 2ΔCt (cycle threshold) method was used to calculate expression levels. Gene 
name symbols with corresponding full names and the list of corresponding primer sequences are 
indicated in Supplementary Table I. 
Cell Growth and Viability. Two thousand tumor cells per well were seeded into 96-well plates and 
cultured for 72 h in the presence of increasing concentrations (0-1000 ng) of recombinant human 
TRAIL (rhTRAIL - R&D Systems). Cell growth and viability were determined using a stable tetrazolium 
salt WST-1 cell proliferation reagent assay kit (Roche, Penzberg, Germany). After the culture period 
and addition of the WST-1 reagent, the absorbance was then determined at 490 nm. The IC50 were 
calculated using Graph Pad Prism v6.01 software. 
Flow Cytometry Analysis. TRAIL staining: Cells were stained with PE-anti-TRAIL (Biolegend) and 
isotype controls (Becton Dickinson). Intracellular staining on transduced AD-MSC was performed with 
a BD Cytofix/Cytoperm kit (Becton Dickinson) using the PE-anti-TRAIL antibody. Annexin V assay: Ten 
thousand MSC-TRAIL or MSC-GFP cells were seeded into 6-well plates. The next day, tumor cells 
were added and co-cultured at a tumor cell/AD-MSC ratio of 3:1. After 48h, the cells were detached 
and stained for the Annexin V assay (BD Bioscience, Franklin Lakes, USA). The percentage of tumor 
cell apoptosis was quantiﬁed by cytometry gating on GFP negative cells with the FC500 flow 
cytometer (Beckman Coulter, Fullerton, USA). 
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Effect of MSC supernatant on tumor cells. Five thousand MSC-TRAIL or MSC-GFP cells were seeded 
into 24-well plates. The next day, two thousand tumor cells were added to Boyden chamber inserts 
of 3 micron porosity in 24-well plates (BD Bioscience). After 48h, the cells in the inserts were fixed 
with 2% Glutaraldehyde (Sigma-Aldrich, Saint-Louis, USA) and stained with 0.5% Crystal Violet in 
ethanol (Sigma-Aldrich). To calculate tumor cell proliferation, the inserts were photographed and the 
cell surface were analyzed with imageJ software (NIH). The results are reported as a percentage of 
tumor cell proliferation in the presence of MSC-GFP control. 
Caspase 3/7 enzymatic activity 
Caspase 3/7 activity was measured using an Apo-ONE® Homogeneous assay kit (Promega). Briefly, 
cells were lysed in RIPA buffer (10 mM Tris pH8, 1 mM EDTA, 150 mM NaCl, 1% NP40, 0.1% SDS) 
containing a cocktail of protease and phosphatase inhibitors (1 mM sodium orthovanadate 
(Na2VO4), 1 mM phenylmethylsulforyl fluoride (PMSF), 10 mM sodium fluoride (NaF), 10 mM N-
ethylmaleimide (NEM), 2 μg/ml leupeptin and 1 μg/ml pepstatine) at 4°C. An equal volume of 
reagents was added to a white-walled 96-well plate containing protein extracts and incubated at 
room temperature for 16h. The fluorescence of each sample was measured in a plate-reading Tristar 
LB941 (Berthold technologies). The data shown concern the concentration of total protein 
determined with a BCA kit (Sigma, St Quentin-Fallavier, France). 
 
In Vivo Experiments 
Ewing sarcoma animal models. Four-week-old Rj:NMRI-nude mice (Janvier Labs - Le Genest-Saint-
Isle, France) were housed under pathogen-free conditions at the Experimental Therapy Unit (Faculty 
of Medicine, Nantes, France) in accordance with the institutional guidelines of the French Ethical 
Committee (CEEA Pays de la Loire n°6) and under the supervision of authorized investigators 
(protocol authorization n°1281.01). The mice were anesthetized by inhalation of an isoflurane/air 
mixture before receiving an intramuscular injection of 106 TC-71 or A-673 EWS cells in close proximity 
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to the tibia. The tumor volume (V) was calculated by measuring three perpendicular diameters with a 
caliper, according to the following formula: V = 0.5 × length × width x height. The mice were 
sacrificed for ethical reasons when tumor volume reached 1 800 mm3. 
Histology. One million MSC-TRAIL or MSC-GFP were injected into established tumors of 
approximately 200 mm3. After 24h, tumor specimens were fixed in formalin and embedded in 
paraffin by conventional techniques. Immunofluorescence double staining with a sequential 
approach was used to demonstrate the simultaneous presence of cleaved-caspase-3 (CC3) and GFP 
(modified MSC) in the tumor. Tissue sections (3µm) were blocked (Blocking reagent 1) and 
pretreated in pH6 citrate buffer. Slides were incubated at 20°C with CC3 primary antibody then with 
A957-conjugated secondary antibody. Slides were blocked at 4°C overnight with IgG Fab goat anti-
rabbit. Sections were incubated at 20°C with GFP primary antibody then with A488-conjugated 
secondary antibody. Slides were mounted in Prolong Gold antifading reagent with DAPI (Molecular 
Probes – P36935). The primary antibodies, fluorochrome-conjugated antibodies and blocking reagent 
used in this study are listed in Supplementary Table II. Fluorescence was visualized using an Axiovert 
200 M microscopy system (Zeiss, Le Pecq, France) with the ApoTome module (x63) or with a 
fluorescent slide scanner (Nanozoomer, Hamamatsu). 
 
Statistical analyses 
Each experiment was repeated independently 3 times. The results are given as a mean ± SD for in 
vitro experiments and a mean ± SEM for in vivo experiments. They were compared using an unpaired 
t test or two-way ANOVA followed respectively by the Bonferroni post-test or the Tukey's multiple 
comparisons test using Graph Pad Prism v6.01 software. Results with p < 0.05 were considered 
significant and are represented by an asterisk (*), p < 0.01 results are represented by two asterisks 
(**) and p < 0.001 by three asterisks (***). 
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Results 
Confirmation of GFP and TRAIL transduction efficiency in MSC-GFP and MSC-TRAIL. AD-MSC were 
transduced in a stable manner with vector encoding full-length human TRAIL (MIGR1-TRAIL-GFP) and 
with control vector (MIGR1-GFP). After 3 passages, fluorescent microscopy (Figure 1A) and 
cytometry analysis (Figure 1B) confirmed that more than 98% of the transduced MSC were GFP 
positive. RT-qPCR analyses showed that MSC-GFP constitutively expressed negligible TRAIL mRNA 
levels (Figure 1C), with protein levels that were below the ELISA detection limit (Figure 1D). In 
contrast, gene modification of the MSCs with TRAIL-encoding vector made high mRNA levels possible 
(Figure 1C), as well as relevant protein expression (8 ng/mg protein extract, Figure 1D). However, 
very small amounts of soluble TRAIL, around 0.1 ng/mL after 48h, were recovered from the 
supernatant (Figure 1E), indirectly indicating that TRAIL is mainly expressed in its membrane form. 
This was confirmed by flow cytometry analysis, showing that TRAIL expression was exclusively 
present in AD-MSC TRAIL, both as a surface and a intracellular protein (Figure 1F). 
AD-MSC delivering TRAIL was able to overcome rhTRAIL resistance in six Ewing sarcoma cell lines. 
Proliferation assays in the presence of rhTRAIL showed that the EWS cell lines studied did not 
respond to rhTRAIL to the same extent (Figure 2A): Ewing sarcoma cell lines TC-71 and RD-ES were 
highly sensitive to the anti-proliferative effect of rhTRAIL (IC50 < 200ng/mL), A-673 and SK-N-MC cell 
lines were less responsive with an IC50 < 1000ng/mL. This pro-apoptotic effect was confirmed by 
caspase-3 enzymatic activity (Figure 2B). The other cell lines (EW-24 and SK-ES-1) were resistant to 
the highest rhTRAIL concentration (IC50 >1000ng/mL).  
On the contrary, when the EWS cell lines were challenged by TRAIL delivered by AD-MSC (Figure 3 A, 
B), all cell lines showed induction of apoptosis, even the initially rhTRAIL-resistant cell lines. This 
sensitivity was demonstrated by apoptosis cytometry assay for two representative cases: rhTRAIL-
sensitive TC-71 and rhTRAIL-resistant SK-ES-1 cells (Figure 3A). 
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We then decided to assess whether this anti-cancer effect was mediated by membrane- or soluble 
forms of TRAIL, or both (Figure 3C). Tumor cells in Boyden chambers overhanging MSC-TRAIL did not 
slow their proliferation when compared to tumor cells in Boyden chambers overhanging MSC-GFP 
(illustration for TC-71 and SK-ES-1 in Figure 3D). These results show that a direct cell-to-cell contact 
between EWS cells and MSC-TRAIL is necessary for cell death to be induced, indirectly suggesting 
that the amount of TRAIL released by MSC-TRAIL is not enough to reduce proliferation in cell lines. 
MSC-TRAIL inhibit tumor progression when co-injected with EWS cells in vivo in two orthotopic 
models. Based on in vitro data showing that TC-71 cells have the highest sensitivity to both rhTRAIL 
and MSC-TRAIL, we developed a para-tibial orthotopic tumor model to verify the impact of MSC-
TRAIL in vivo in the relevant corresponding animal model. Either 106 TC-71 cells alone or TC-71 
combined with 106 of MSC-TRAIL or MSC-GFP were injected once at Day 0 (D0). The group inoculated 
with MSC-GFP showed the same tumor progression as the control group (Figure 4A). On the 
contrary, one dose of MSC-TRAIL injection was enough to abolish tumor development by 75% on 
tumor growth starting from D20 (Figure 4A, B). This was associated with a significant impact on 
survival rate (calculated when tumor volume reached 1500 mm3), which increased by 60% in the 
group co-injected with MSC-TRAIL (Figure 4C). Macroscopic pulmonary metastases were not 
detected in any of the groups studied (Figure 4D).  After 26 days of tumor proliferation, tumor cell 
isolation in the MSC-GFP treated group showed that less than 0.25% of the cells were GFP positive, 
indicating that MSC did not proliferate in tumors (Figure 4E). 
To further challenge the MSC-TRAIL strategy, we established an additional para-tibial orthotopic 
tumor model using the highly proliferating A-673 line that showed less sensitivity to rhTRAIL than TC-
71 cells. Thus, 106 A-673 cells alone or with one dose of 106 of MSC-TRAIL or MSC-GFP were injected 
at D0. The A-673 line confirmed its aggressiveness in vivo, with rapid generation of large tumors in 
less than 20 days (Figure 5A, B). Although there was no difference in the survival rate of the mice 
(calculated when tumor volume reached 1200 mm3) injected with A-673 alone or A-673 with MSC-
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GFP (Figure 4C), the group co-injected with MSC-GFP showed a slight, though significant, 
acceleration in tumor growth when compared to the control group (Figure 5A, B). Despite the pro-
tumoral effect of MSC-GFP, the injection with MSC-TRAIL controlled tumor growth and tumors were 
barely detectable in the MSC-TRAIL group, with a tumor volume of less than 80 mm3 at 20 days 
(Figure 5A, B). As a consequence, the survival rate increased significantly in the group co-injected 
with MSC-TRAIL and A-673 cells, and the mice developed significant tumor volumes only 40 days 
after the injection time, surviving for more than 70 days, despite the aggressiveness of the A-673 cell 
line (Figure 5C). 
However, when MSC-TRAIL were injected into established tumors, only a transient significant 
inhibitory effect could be observed around day 5, but this did not affect animal survival 
(Supplementary Figure S1). 
In vivo MSC-TRAIL induce apoptosis in adjacent Ewing sarcoma tumor cells. To investigate the anti-
tumorigenic effect of MSC-TRAIL in situ, mice were injected with A-673 cells to generate tumors 
rapidly. When their volume reached 200 mm3, either one million MSC-GFP or MSC-TRAIL were 
injected into the tumors (n=3). Immunofluorescence analyses of the EWS model showed that MSC-
TRAIL injected into the tumor were able to induce apoptosis of adjacent A-673 EWS cells, as revealed 
by the detection of cleaved caspase-3 by immunofluorescence (Figure 5D). This effect remained 
local, as the presence of active caspase-3 was only localized around the injected MSC-TRAIL on a total 
histological section of the tumor (Figure 5E). On the contrary, MSC-GFP injection did not induce 
apoptosis in adjacent EWS cells. 
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Discussion 
The ability of TRAIL to induce tumor apoptosis and death without affecting normal cells makes it a 
very interesting tool for tumor therapy. However, many types of cancer remain resistant to TRAIL, 
including sarcomas 21,22. Finding relevant and diversified strategies to overcome this resistance seems 
to be an essential prerequisite for offering patients new therapeutic options. 
MSC can be engineered to express TRAIL and a recent study has demonstrated that these cells can 
induce apoptosis in a variety of sarcomas (osteosarcoma, rhabdomyosarcoma, EWS) by activation of 
caspase-820, paving the way for MSC-TRAIL-based therapies in these still deathly forms of cancer. 
Here, we further confirm these findings by focusing on EWS and demonstrating that AD-MSC 
delivering TRAIL can induce apoptosis in a wide panel of EWS cell lines in vitro. All the cell lines 
considered were sensitive to apoptosis induced by MSC-TRAIL, suggesting that the extrinsic apoptosis 
signaling pathway is functional in all these cell lines. This appears to be in contrast with the data, 
suggesting that some of these lines are resistant to relatively high amounts of rhTRAIL. While this 
finding requires further investigation, we can currently hypothesize that MSC-TRAIL is able to induce 
significant clustering of death receptors at the surface of EWS cells, multiplying the downstream 
activation of caspase-8. A study with liposome-bound TRAIL reports that higher DR5 clustering 
enhances DISC formation and triggers caspase activation more efficiently than the soluble form of 
rhTRAIL23. In addition, a second TRAIL signaling pathway has recently been described, involving NF-
kB, MAPK, PI3K/Akt activation via binding to the same receptors, but leading to increased tumor cell 
proliferation, survival, migration and invasion (reviewed in 24). The key regulator of this kinase 
network is the RIPK1 protein, which binds FADD instead of caspase-8, inducing the formation of a 
secondary signaling complex composed of TRADD, TRAF2 and RIPK1. We can further hypothesize that 
rhTRAIL can activate this secondary pathway that counteracts its pro-apoptotic effect, whereas high 
clustering of MSC-TRAIL and death receptors may associate several caspase-8 molecules which 
overcome the formation of the RIPK1-TRADD-TRAF2 complex. The evidence that only direct contact 
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between EWS cells and MSC-TRAIL can induce apoptosis supports the concept that a high level of 
death receptor clustering is necessary for apoptosis induction via DISC formation. The need for cell-
to-cell contact for AD-MSC TRAIL delivery has been also reported in a cervical carcinoma cell line18. 
However, our study is the first evidence provided in several sarcoma cell lines, indicating that a cell 
delivery approach for TRAIL may be far more efficient than rhTRAIL alone, indicating the need for 
dedicated strategies to drive MSC homing and persistence inside tumors. 
A previous study showed that MSC-TRAIL can exert relevant antitumor activity against a 
subcutaneous xenograft model of RD-ES EWS cells20. However, we felt that in these neoplastic 
disorders so closely related to skeletal tissues, more relevant orthotopic models needed to be 
introduced, taking into account their peculiar tumor microenvironment. For this reason, we 
introduced two different para-tibial orthotopic EWS models. Confirming early data obtained in a EWS 
sub-cutaneous model, tumor progression was counteracted by a single dose of MSC-TRAIL, 
underlining the therapeutic potential of this approach and indicating the need for delivery 
optimization with a different schedule (multiple deliveries) for MSC-TRAIL or with MSC delivering 
soluble variants of TRAIL.  
It has been shown that MSC expressing TRAIL were able to reduce the incidence of lung metastases 
in carcinoma models15. However, this effect was not observed in our EWS mouse models as the cells 
were highly aggressive with too rapid progression that was not enough to develop and observe 
spontaneous metastases. We therefore cannot conclude on the effect of MSC-TRAIL on the 
occurrence of metastases in these models, and dedicated EWS metastatic models are needed to 
clarify this aspect. 
We also report that in one of the para-tibial orthotopic EWS model obtained with the A-673 EWS 
line, the MSC-GFP enhanced tumor progression, as previously described with the HeLa cell line18. 
Several studies have reported that MSC may have the ability to promote cancer growth, particularly 
by increasing angiogenesis, releasing chemokines or interfering with cancer metabolism25–28. This 
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effect observed in osteosarcoma syngeneic and xenograft mouse models29,30 seems to be an obstacle 
to the use of MSCs as therapeutic tools in bone tumor pathologies. However, other results suggest 
that MSCs inhibit tumor growth, especially by inhibiting the Wnt pathway31–35. A concise review 
categorizes both MSC pro- or anti-tumor effects depending on different tumor types and 
microenvironments36. Therefore, understanding the conditions in which MSC may enhance tumor 
growth is crucial for safely developing MSCs as a therapeutic tool.  
In conclusion, we have shown that AD-MSCs delivering TRAIL can counteract EWS growth both in 
vitro and in vivo within two different orthotopic EWS models. Efforts will now focus on solidifying the 
strategy in order to safely transfer MSCs as therapeutic tools for EWS, starting with deeper 
understanding of the conditions in which MSCs may influence tumor growth before properly defining 
delivery approaches. However, the use of MSC-TRAIL evidenced that a high death receptor 
membrane presentation is able to induce apoptosis in cell lines initially resistant to rhTRAIL in vitro. 
This clustering strategy is very promising and can be conducted with more neutral TRAIL vectors, 
such as new TRAIL death receptor agonists capable of bind six receptors37. 
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